0
0
0
0
Smart Citations
0
0
0
0
Citing PublicationsSupportingMentioningContrasting
View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma

Authors

Background Panobinostat (LBH589) is a potent pan-deacetylase inhibitor (DACi) which has demonstrated activity in patients (pts) with CTCL in a Phase I study (Prince et al., ASCO 2007).

Supporting Agencies

How to Cite

Bernengo, M., Vanaclocha, F., Duvic, M., Kuzel, T., Kerdel, F., Pinter-Brown, L., Bosly, A., Okada, C., Breneman, D., Zinzani, P., Becker, J., Hughey, L., Ardaiz, M., Zain, J., & Zhang, L. (2009). A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.725